Cancer treatment in the lymphatic system: A prospective targeting employing nanostructured systems

Autor(es):Mostrar menos -

Yukuyama, Megumi Nishitani ^[1] ; de Araujo, Gabriel Lima Barros ^[1] ; de Souza, Aline ^[1] ; Lobenberg, Raimar ^[2] ; Barbosa, Eduardo Jose ^[1] ; Henostroza, Mirla Anali Bazan ^[1] ; Rocha, Nataly Paredes da ^[1] ; Oliveira, Isabela Fernandes de ^[1] ; Folchini, Beatriz Rabelo ^[1] ; Peroni, Camilla Midori ^[1] ; Masiero, Jessica Fagionato ^[1] ; Bou-Chacra, Nadia Araci ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept Pharm, Fac Pharmaceut Sci, Ave Prof Lineu Prestes 508, Sao Paulo, SP - Brazil

^[2] Univ Alberta, Rexall Ctr Pharm & Hlth Res, Fac Pharm & Pharmaceut Sci, Div Pharmaceut Sci, Katz Grp, 11361-87 Ave, Room 3-142-K, Edmonton, AB T6G 2E1 - Canada

• Tipo de documento: Artigo Científico
• Fonte: International Journal of Pharmaceutics; v. 587, SEP 25 2020.
• Citações Web of Science: 0

Resumo

Cancer related to lymphangiogenesis has gained a great deal of attention in recent decades ever since specific markers of this intriguing system were discovered. Unlike the blood system, the lymphatic system has unique features that can advance cancer in future metastasis, or, conversely, can provide an opportunity to prevent or treat this disease that affects people worldwide. The aim of this review is to show the recent research of cancer treatment associated with the lymphatic system, considered one of the main gateways for disseminating metastatic cells to distant organs. Nanostructured systems based on theranostics and immunotherapies can offer several options for this complex disease. Precision targeting and accumulation of nanomaterials into the tumor sites and their elimination, or targeting the specific immune defense cells to promote optimal regression of cancer cells are highlighted in this paper. Moreover, therapies based on nanostructured systems through lymphatic systems may reduce the side effects and toxicity, avoid first pass hepatic metabolism, and improve patient recovery. We emphasize the general understanding of the association between the immune and lymphatic systems, their interaction with tumor cells, the mechanisms involved and the recent developments in several nanotechnology treatments related to this disease. (AU)

• Processo FAPESP: 18/22713-2 - Estudo do reposicionamento do flubendazol para o tratamento de câncer de pulmão e meningoencefalite empregando nanossistema lipídico oral
• Beneficiário: Megumi Nishitani Yukuyama
• Modalidade de apoio: Bolsas no Brasil - Doutorado